Category Archives: Pharmacokinetics & Pharmacodynamics

Selectively Targeting Metabolism in Mitochondria In Cancer Cells

An experimental drug, CPI-613, was shown to be safe and induce several responses in a Phase I study of patients with advanced refractory hematologic malignancies. The drug targets mitochondrial enzymes of cancer cells and is not harmful to normal cells at therapeutic doses. Continue reading

Targeted Nanoparticles for Cancer – optimizing physiochemical properties for enhanced tumor-killing

Last week, BIND Therapeutics and Amgen ended a collaboration on a targeted nanaoparticle that employed a proprietary cytotoxic compound from Amgen.  However, BIND has several other programs (and partnerships with AstraZeneca, Roche, and Pfizer) that are proceeding in the clinic, which employ its Targeted Nanoparticle (TNP) technology.  How does this work? Continue reading